AcelRx Pharmaceuticals (NASDAQ:ACRX), A reduction of 103,526 shares or 2.9% was observed in the short interest of AcelRx Pharmaceuticals, Inc. The interest on June 15,2016 came in at 3,529,541 shares and as per the average daily trading of 188,604 shares, the days to cover are 19. The reduced interest is 11.8% of the floated shares. The data of May 31,2016 put the interest at 3,633,067 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
AcelRx Pharmaceuticals (NASDAQ:ACRX): The stock opened at $2.60 on Friday but the bulls could not build on the opening and the stock topped out at $2.65 for the day. The stock traded down to $2.56 during the day, due to lack of any buying support eventually closed down at $2.57 with a loss of -5.86% for the day. The stock had closed at $2.73 on the previous day. The total traded volume was 4,021,180 shares.
The company shares have dropped -35.75% from its 1 Year high price. On Nov 24, 2015, the shares registered one year high at $5.88 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $3.19 and the 200 Day Moving Average price is recorded at $3.49.
AcelRx Pharmaceuticals (NASDAQ:ACRX) has tumbled 10.14% during the past week and has dropped 26.15% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 8.65%. AcelRx Pharmaceuticals (NASDAQ:ACRX) has underperformed the index by 23.92% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Companys lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.